Sanofi, ABL Bio Join to Develop ABL301 as Potential Treatment

ABL Bio and Sanofi are working under a global licensing agreement to jointly develop ABL301 — an investigational bispecific antibody targeting both alpha-synuclein and insulin-like growth factor 1 receptor (IGF1R) — in possibly treating Parkinson’s disease. Under the agreement, ABL Bio will lead further preclinical testing and a…